Results 121 to 130 of about 121,700,018 (217)

Xeomin^®, a Commercial Formulation of Botulinum Neurotoxin Type A, Promotes Regeneration in a Preclinical Model of Spinal Cord Injury. [PDF]

Toxins (Basel), 2023
Mastrorilli V, De Angelis F, Vacca V, Pavone F, Luvisetto S, Marinelli S.   +5 more
europepmc   +1 more source

Botulinum Neurotoxin Type A Directly Affects Sebocytes and Modulates Oleic Acid-Induced Lipogenesis. [PDF]

Toxins (Basel), 2022
Brami-Cherrier K, Chernavsky A, You H, Grando SA, Brideau-Andersen A, Sondergaard B.   +5 more
europepmc   +1 more source

Complications After Botulinum Neurotoxin Type A and Dermal Filler Injections: Data From a Large Retrospective Cohort Study. [PDF]

Aesthet Surg J, 2023
Steenen SA, Bauland CG, de Lange J, van der Lei B.   +3 more
europepmc   +1 more source

Regional Targeted Subcutaneous Injection of Botulinum Neurotoxin Type A in Refractory Chronic Migraine: A Randomized, Double-Blind, Placebo-Controlled Study. [PDF]

Toxins (Basel), 2023
Bono F, Mazza MR, Magro G, Spano G, Idone G, Laterza V, Tedeschi D, Pucci F, Gambardella A, Sarica A.   +9 more
europepmc   +1 more source

Presynaptic targeting of botulinum neurotoxin type A requires a tripartite PSG-Syt1-SV2 plasma membrane nanocluster for synaptic vesicle entry. [PDF]

EMBO J, 2023
Joensuu M, Syed P, Saber SH, Lanoue V, Wallis TP, Rae J, Blum A, Gormal RS, Small C, Sanders S, Jiang A, Mahrhold S, Krez N, Cousin MA, Cooper-White R, Cooper-White JJ, Collins BM, Parton RG, Balistreri G, Rummel A, Meunier FA.   +20 more
europepmc   +1 more source

Botulinum Neurotoxin Type a Injection Combined with Absorbable Punctal Plug Insertion: An Effective Therapy for Blepharospasm Patients with Dry Eye. [PDF]

J Clin Med, 2023
Ndikumukiza M, Xiao YT, Ye YF, Wang JS, Peng X, Xie HT, Zhang MC.   +6 more
europepmc   +1 more source

New Modified Recombinant Botulinum Neurotoxin Type F with Enhanced Potency. [PDF]

Toxins (Basel), 2021
Burgin D, Périer C, Hackett G, Elliott M, Kwan D, Hornby F, Mir I, Maignel J, Liu SM, Beard M.   +9 more
europepmc   +1 more source

Development and Humanization of a Camelid-Derived Neutralizing Nanobody Targeting Botulinum Neurotoxin Type A. [PDF]

Int J Nanomedicine
Jiang Y, Xin W, Lu J, Wang R, Guo J, Du P, Gao C, Yu Y, Yang Z.   +8 more
europepmc   +1 more source

Evaluation of Recombinant Botulinum Neurotoxin Type A1 Efficacy in Peripheral Inflammatory Pain in Mice. [PDF]

Front Mol Neurosci, 2022
Oehler B, Périer C, Martin V, Fisher A, Lezmi S, Kalinichev M, McMahon SB.   +6 more
europepmc   +1 more source

Transcriptional Profiling of Botulinum Neurotoxin Type A-Related Molecular Components in Primary Human Schwann Cells. [PDF]

Toxins (Basel)
Sánchez-Carranza O, Jatzke C, Gravius A, Nagel J.   +3 more
europepmc   +1 more source